IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR
개요
출원인
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES; Washington University
발명자
Lisa Lynn CUNNINGHAM; Cathy Yea Won SUNG; Mark E. WARCHOL
IPC 분류
CPC 분류
Disclosed is a method of impeding platinum-based chemotherapeutic induced ototoxicity, and/or other toxicity, the method comprising administering a colony stimulating factor 1 receptor (CSF1R) inhibitor to a subject in an amount sufficient to impede ototoxicity, and/or other toxicity, inducible by a platinum-based chemotherapeutic; and administering the platinum-based chemotherapeutic to the subject. The CSF1R inhibitor can be, for example, pexidartinib. The platinum-based chemotherapeutic can be, for example, cisplatin. Compositions, medicaments, kits, and uses are disclosed related to the same. Further, a method of screening for a compound able to impede a platinum-based chemotherapeutic induced toxicity is disclosed.
원문 (중국어)
Disclosed is a method of impeding platinum-based chemotherapeutic induced ototoxicity, and/or other toxicity, the method comprising administering a colony stimulating factor 1 receptor (CSF1R) inhibitor to a subject in an amount sufficient to impede ototoxicity, and/or other toxicity, inducible by a platinum-based chemotherapeutic; and administering the platinum-based chemotherapeutic to the subject. The CSF1R inhibitor can be, for example, pexidartinib. The platinum-based chemotherapeutic can be, for example, cisplatin. Compositions, medicaments, kits, and uses are disclosed related to the same. Further, a method of screening for a compound able to impede a platinum-based chemotherapeutic induced toxicity is disclosed.